Schering Corporation

Opko Health, Inc.

Pfizer Corporation

Scherig Corporation

Gregory A Reichard

Neng-Yang Shih

Dong Xiao

Sunil Paliwal

Cheng Wang

Hon-Chung Tsui

Michelle Laci Wrobleski

Anandan Palani

Juan D Arredondo

John J Piwinski

Robert G Aslanian

Pauline C Ting

Nicholas I Carruthers

Cheryl A Alaimo

Dasong Wang

Ashit K Ganguly

Kevin D McCormick

David J Blythin

Bandarpalle B Shankar

Ho-Jane Shue

Pietro Mangiaracina

Xiao Chen

Michael P Kirkup

James M Spitler

Andrew Lupo, Jr

Brian J Lavey

Jonathan A Pachter

Shelly Ann Glase

David L Gray

Nancy Sue Barta

Elmer J Mirro

Dineshwar Sinha

Michael W Leach

Mark E Cartwright

Mark R Berardi

Steven Wang

Sapna Majmundar Shah

Wenijan Xu

Lloyd Jerome Simons

A NKantagonist having the formula (I), wherein Arand Arare optionally substituted phenyl or heteroaryl, Xis an ether, thio or imino linkage, Rand Rare not both H or alkyl, and the remaining variables are as defined in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceutical compositions. Methods of treatment and combinations with other agents are also disclosed.

[object Object]

NK1 antagonists

This invention relates to compounds of the formulae I wherein R-R, A, X, and Z are defined as in the specification, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.

Substituted morpholine compounds for the treatment of central nervous system disorders

A compound having the general structure shown in Formula 1: or pharmaceutically acceptable salts and/or solvates thereof are useful in treating diseases or conditions mediated by NKreceptors, for example various physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough.

A NKantagonist having the formula (I),wherein Arand Arare optionally substituted phenyl or heteroaryl, Xis an ether, thio or imino linkage, Rand Rare not both H or alkyl, and the remaining variables are as defined in the in the specification, useful for treating a number of disorders, including emesis, depression, anxiety and cough. Pharmaceuticals compositions. Methods of treatment and combinations with other agents are also disclosed.

Disclosed are NKantagonists having the formula: Also disclosed are methods for treating a number of physiological disorders, symptoms or diseases, including emesis, depression, anxiety and cough, using the compounds of formula (I).

A NKantagonist having the formula (I), with the variables defined herein, which is useful for treating a number of disorders, including emesis, depression, anxiety and cough:

Selective neurokinin antagonists

Use of an antagonist selected from the group consisting of: (a) antagonists of neurokinin-1 (NK ), neurokinin-2 (NK ) and neurokinin-3 (NK ) receptors, (b) antagonists of NK and NK receptors, (c) antagonists of NK and NK receptors, (d) antagonists of NK and NK receptors, (e) antagonists of NK receptors, and (f) antagonists of NK to treat symptoms and disorders associated with a production and/or secretion of androgen. One aspect of the invention relates to the use of antagonists to suppress production/secretion of androgens in mammals suffering from an androgen-dependent disease, such as benign prostatic hyperplasia and prostatic carcinoma.

Use of neurokinin receptor antagonists to treat androgen-dependent diseases

Substituted oximes and hydrazones as neurokinin antagonists

Growing community of inventors

Ann Arbor, MI, United States of America

Gregory A Reichard